Savella Related Published Studies
Well-designed clinical trials related to Savella (Milnacipran)
Prevention of poststroke depression with milnacipran in patients with acute ischemic stroke: a double-blind randomized placebo-controlled trial. [2011.09]
The dubious effect of milnacipran for the treatment of burning mouth syndrome. [2011.07]
The dubious effect of milnacipran for the treatment of burning mouth syndrome. [2011]
Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial. [2010.09]
Contributions of change in clinical status parameters to Patient Global Impression of Change (PGIC) scores among persons with fibromyalgia treated with milnacipran. [2010.05]
A European multicenter randomized double-blind placebo-controlled monotherapy clinical trial of milnacipran in treatment of fibromyalgia. [2010.04]
Effects of milnacipran on cardiac repolarization in healthy participants. [2010.04]
Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension study. [2010.02]
[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study] [2009.12]
Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine. [2009.11.13]
The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. [2009.02]
Milnacipran for the treatment of fibromyalgia in adults: a 15-week, multicenter, randomized, double-blind, placebo-controlled, multiple-dose clinical trial. [2008.11]
The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. [2008.10]
Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. [2008.08]
Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment. [2008]
Efficacy and Tolerability of Milnacipran in the Treatment of Major Depression in Comparison with Other Antidepressants : A Systematic Review and Meta-Analysis. [2008]
Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. [2007.06.30]
A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. [2007.01]
Well-designed clinical trials possibly related to Savella (Milnacipran)
Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled
randomized trials. [2011]
Other research related to Savella (Milnacipran)
Sleep disturbance associated with an enhanced orexinergic system induced by chronic treatment with paroxetine and milnacipran. [2011.07]
Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study. [2011.06.03]
Fluoxetine, desipramine, and the dual antidepressant milnacipran reduce alcohol self-administration and/or relapse in dependent rats. [2011.06]
Can milnacipran used for neuropathic pain in patients with advanced cancer cause neuromuscular and somatosensory disorders? [2011.04]
Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain. [2011.03.25]
Comparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis. [2011.03]
A pooled analysis of two randomized, double-blind, placebo-controlled trials of milnacipran monotherapy in the treatment of fibromyalgia. [2011.03]
Intranasal administration of milnacipran in rats: evaluation of the transport of drugs to the systemic circulation and central nervous system and the pharmacological effect. [2011]
Prevention of poststroke depression with milnacipran in patients with acute
ischemic stroke: a double-blind randomized placebo-controlled trial. [2011]
In vivo canine model comparison of cardiovascular effects of antidepressants milnacipran and imipramine. [2010.12]
Monoamine-dependent, opioid-independent antihypersensitivity effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a postoperative pain model in rats. [2010.09.01]
Milnacipran for treatment of fibromyalgia. [2010.09]
A Pooled Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials of Milnacipran Monotherapy in theTreatment of Fibromyalgia. [2010.07.19]
Effectiveness and safety of milnacipran treatment for a patient with delusional disorder, somatic type taking multiple medications for concomitant physical diseases. [2010.07]
Comparative efficacy and harms of duloxetine, milnacipran, and pregabalin in fibromyalgia syndrome. [2010.06]
Effectiveness of milnacipran for a patient with pain disorder and long QT syndrome. [2010.05]
Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study. [2010.04.07]
[Prediction of antidepressant response to milnacipran and fluvoxamine using pharmacogenetical methods] [2010.04]
Effectiveness of milnacipran for the treatment of chronic pain in the orofacial region. [2010.03]
Effect of acute and chronic treatment with milnacipran potentiates the anticonvulsant activity of conventional antiepileptic drugs in the maximal electroshock-induced seizures in mice. [2010.01]
Milnacipran: in fibromyalgia. [2010]
Contributions of change in clinical status parameters to Patient Global
Impression of Change (PGIC) scores among persons with fibromyalgia treated with
milnacipran. [2010]
Durability of therapeutic response to milnacipran treatment for fibromyalgia.
Results of a randomized, double-blind, monotherapy 6-month extension study. [2010]
Milnacipran: beyond a role of antidepressant. [2009.11]
Analgesic effect of milnacipran is associated with c-Fos expression in the anterior cingulate cortex in the rat neuropathic pain model. [2009.08]
Milnacipran versus other antidepressive agents for depression. [2009.07.08]
Milnacipran: Beyond a Role of Antidepressant. [2009.06.10]
Effect of the combined use of tramadol and milnacipran on pain threshold in an animal model of fibromyalgia. [2009.06]
Functional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipran. [2009.06]
Therapeutic effects of the selective serotonin noradrenaline reuptake inhibitor milnacipran on depressive symptoms in patients with Alzheimer's disease. [2009.03.17]
[Acute prostatism associated with milnacipran therapy: a case report] [2009.01]
Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan. [2008.12.31]
Lubiprostone--a novel treatment for irritable bowel syndrome with constipation. [2008.09]
A case of severe parkinsonism associated with short-term treatment with milnacipran. [2008.09]
Fatal intoxication with milnacipran. [2008.08]
No predictors of antidepressant patient response to milnacipran were obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale in Japanese patients with major depressive disorders. [2008.04]
Antiallodynic and antihyperalgesic effect of milnacipran in mice with spinal nerve ligation. [2008.04]
Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. [2008.03]
Milnacipran attenuates hyperalgesia and potentiates antihyperalgesic effect of tramadol in rats with mononeuropathic pain. [2007.12]
Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients. [2007.08]
[The clinical efficacy of SNRI milnacipran in the treatment of hot flushes with prostate cancer hormonally treated] [2007.06]
Successful treatment of trigeminal neuralgia with milnacipran. [2007.05]
The efficacy of milnacipran in panic disorder: an open trial. [2007.05]
Other possibly related research studies
Fibromyalgia: diagnosis and treatment options. [2009]
The psychiatrist confronted with a fibromyalgia patient. [2009.06]
Effects of antidepressants on GluR2 Q/R site-RNA editing in modified HeLa cell line. [2009.07]
Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. [2009.05]
Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. [2009.02.28]
Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder. [2009.04.30]
Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. [2008.07]
Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. [2008.07]
Treating depression with SNRIs: who will benefit most? [2008.07]
Initial effectiveness, partial remission, and full remission in depression: focus on long-term treatment with SNRIs. [2008.07]
Effects of intrathecal administration of newer antidepressants on mechanical allodynia in rat models of neuropathic pain. [2009.01]
Pragmatic consideration of recent randomized, placebo-controlled clinical trials for treatment of fibromyalgia. [2008.12]
A systematic review on the effectiveness of treatment with antidepressants in fibromyalgia syndrome. [2008.09.15]
Are SNRIs More Effective than SSRIs? A Review of the Current State of the Controversy. [2008]
Is co-administration of bupropion with SSRIs and SNRIs in forced swimming test in mice, predictive of efficacy in resistant depression? [2008.12.01]
Two cases of burning mouth syndrome treated with olanzapine. [2008.06]
Duloxetine-induced hypomania: case report and brief review of the literature on SNRIs-induced mood switching. [2009.07]
Pain management in fibromyalgia. [2008.05]
Fibromyalgia: harmonizing science with clinical practice considerations. [2008.05]
Effect of co-administration of a serotonin-noradrenaline reuptake inhibitor and a dopamine agonist on extracellular monoamine concentrations in rats. [2008.04.28]
Relevant issues in the monitoring and the toxicology of antidepressants. [2008]
[Pharmacological treatment of fibromyalgia] [2007.10]
Usefulness of antidepressants for improving the neuropathic pain-like state and pain-induced anxiety through actions at different brain sites. [2008.07]
[Fibromyalgia syndrome : New developments in pharmacotherapy.] [2008.02]
Which antidepressants have demonstrated superior efficacy? A review of the evidence. [2007.11]
Patient satisfaction with antidepressants: an Internet-based study. [2008.04]
[Medication to treat fibromyalgia?] [2007.06.20]
Triple uptake inhibitors: therapeutic potential in depression and beyond. [2007.09]
[Applications and safety of modern antidepressants in patients with liver diseases] [2007]
Association of suicide and antidepressant prescription rates in Japan, 1999-2003. [2007.06]
Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. [2007.12.01]
[Reproducible efficacy of tricyclic antidepressant on chronic pain in an elderly patient with osteoporosis] [2007.03]
A review of SSRIs and SNRIs in neuropathic pain. [2010.07.19]
Fibromyalgia syndrome: practical strategies for improving diagnosis and patient outcomes. [2010.06]
[Possibility of a pharmacogenetic approach for prediction and personalized medication in major depressive disorder treatment] [2010.04]
Assessing anxiolytic-like effects of selective serotonin reuptake inhibitors and serotonin-noradrenaline reuptake inhibitors using the elevated plus maze in mice. [2010.03]
Management of depression in the presence of pain symptoms. [2010.03]
Focus on pain mechanisms and pharmacotherapy in the treatment of fibromyalgia syndrome. [2009.09]
Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. [2010.01]
|
